OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.30

+4.4%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$58.80M
EPS-4.4000
P/E Ratio-0.98
Earnings Date08/11/2026

okur

Capital Lease Obligations (Current)

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Capital Lease Obligations (Current)

OKUR · NASDAQ
CompanyCapital Lease Obligations (Current)
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
36.17K
-13.5%-32.5%N/A
0.00
N/AN/AN/A
3.73M
4.8%5.1%N/A
2.24M
4.4%26.2%N/A
0.00
N/AN/AN/A
580.00K
N/A13.6%N/A
3.86M
4.3%10.9%N/A
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.3, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.3